title: Analysis of the therapeutic effect of tadalafil on male ED after transurethral resection of prostate.
abstract: The objective of this study is to explore the therapeutic effect of Tadalafil on male ED after transurethral resection of prostate (TURP). Using the 5-item version of the International Index of Erectile Function (IIEF-5), ED was assessed in 104 male patients who experienced ED after TURP. These patients were assigned randomly into the therapy group and matched group on the basis of the degree of ED. The patients of the therapy group received Tadalafil, and the patients of matched group received placebo of starch. According to their actual conditions, all patients were informed of the action mechanism and administration of Tadalafil in detail, and advised to use the drug 1 h before sexual activity as recommended. The dose was increased from 10 to 20 mg by week 2 and 4, depending on the effects and adverse reactions. After 8 weeks, ED was re-assessed by IIEF-5. In therapy group, ED was cured in 28 cases, improved in 17 cases, and nonresponsive in 7 cases, with an overall effective rate of 86.5%. In matched group, ED was cured in 6 cases, improved in 7 cases, and non-responsive in 39 cases, with an overall effective rate of 25%. The statistical difference was significant (P<0.05). No significant adverse reaction was observed in any patient. In conclusion, Tadalafil is safe and effective, and can be used as the first-line medication for the clinical treatment of post-TURP ED.
authors.affiliation: Department of Urosurgery, The 2nd Affiliated Hospital of Wenzhou Medical College, Zhejiang, China.
authors.forename: H
authors.initials: H
authors.lastname: Yu
authors.forename: H
authors.initials: H
authors.lastname: Wu
authors.forename: D
authors.initials: D
authors.lastname: Rao
mesh_terms: D000368:Aged; D002243:Carbolines / Q000627:therapeutic use*; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000209:etiology* / Q000523:psychology; D006801:Humans; D008297:Male; D008875:Middle Aged; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000188:drug therapy; D011470:Prostatic Hyperplasia / Q000601:surgery*; D000068581:Tadalafil; D020728:Transurethral Resection of Prostate / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D002243:Carbolines; D058986:Phosphodiesterase 5 Inhibitors; D000068581:Tadalafil